Results 1 to 10 of about 3,221 (198)

Glutaryl-CoA Dehydrogenase Misfolding in Glutaric Acidemia Type 1. [PDF]

open access: yesInt J Mol Sci, 2023
Glutaric acidemia type 1 (GA1) is a neurotoxic metabolic disorder due to glutaryl-CoA dehydrogenase (GCDH) deficiency. The high number of missense variants associated with the disease and their impact on GCDH activity suggest that disturbed protein ...
Barroso M   +8 more
europepmc   +7 more sources

Biochemical and molecular features of chinese patients with glutaric acidemia type 1 from Fujian Province, southeastern China [PDF]

open access: yesOrphanet Journal of Rare Diseases, 2023
Background Glutaric acidemia type 1 (GA1) is a rare autosomal recessive inherited metabolic disorder caused by variants in the gene encoding the enzyme glutaryl-CoA dehydrogenase (GCDH).
Jinfu Zhou   +7 more
doaj   +5 more sources

Biochemical and molecular features of Chinese patients with glutaric acidemia type 1 detected through newborn screening [PDF]

open access: yesOrphanet Journal of Rare Diseases, 2021
Background Glutaric acidemia type 1 (GA1) is a treatable disorder affecting cerebral organic acid metabolism caused by a defective glutaryl-CoA dehydrogenase (GCDH) gene.
Yiming Lin   +6 more
doaj   +6 more sources

A novel mutation in the glutaryl‐CoA dehydrogenase gene (GCDH) in an Iranian patient affected with Glutaric acidemia type 1 [PDF]

open access: yesClinical Case Reports, 2021
Our findings revealed the mutation c.536T>C (p. Leu179Pro) in GCDH gene although has not been reported so far, but the in‐silico analysis and clinical symptoms of the patient indicated that the mutation is pathogenic full stop.
Sima Rayat, Saeid Morovvati
doaj   +6 more sources

Prenatal Ultrasound and Magnetic Resonance Findings of Glutaric Acidemia Type 1 and Its Challenges in Prenatal Diagnosis [PDF]

open access: yesJournal of Medical Ultrasound
Glutaric acidemia type 1 (GA1) presents unique challenges in prenatal diagnosis, especially in cases with no family history. This review article aims to review and present the prenatal ultrasound and magnetic resonance findings of GA1 and consolidate key
Jo-Ting Wang   +2 more
doaj   +5 more sources

Detection of glutaric acidemia type 1 in infants through tandem mass spectrometry [PDF]

open access: yesMolecular Genetics and Metabolism Reports, 2015
Glutaric acidemia type 1 (GA1) is a rare inherited metabolic disorder which goes underdiagnosed due to its latency period and subtle presentation. A pilot clinical study was conducted to assess the usefulness, specificity and sensitivity of the tandem ...
Ruby P. Babu   +6 more
doaj   +5 more sources

Orthopaedic manifestations of glutaric acidemia Type 1. [PDF]

open access: yesJ Child Orthop, 2020
Purpose Glutaric acidemia type 1 (GA1), a rare hereditary metabolic disease caused by biallelic mutations of GCDH, can result in acute or insidious striatal degeneration within the first few years of life.
Imerci A   +3 more
europepmc   +5 more sources

GLUTARIC ACIDEMIA TYPE 1: A CASE REPORT FROM PAKISTAN

open access: yesKhyber Medical University Journal, 2022
INTRODUCTION: Glutaric aciduria type 1 is a neurometabolic disorder occurring due to deficient activity of glutaryl-CoA dehydrogenase. Multiple neurotoxic metabolites start accumulating in plasma, CSF and urine which are detected by mass spectrometry ...
Noshaba Noor, Hira Waseem
doaj   +3 more sources

Case report: Lysine improvement in siblings with glutaric acidemia type 1 following reduced medical food intake: Implications for amino acid absorption and reabsorption [PDF]

open access: yesMolecular Genetics and Metabolism Reports
Glutaric acidemia type 1 (GA1) is a rare metabolic disorder requiring dietary management with lysine (Lys)-free, tryptophan (Trp)-reduced, and arginine (Arg)-fortified medical formulas.
Grace Noh, Jariya Upadia
doaj   +3 more sources

Use of the Novel Site-Directed Enzyme Enhancement Therapy (SEE-Tx) Drug Discovery Platform to Identify Pharmacological Chaperones for Glutaric Acidemia Type 1. [PDF]

open access: yesJ Med Chem
Allosteric regulators acting as pharmacological chaperones hold promise for innovative therapeutics since they target noncatalytic sites and stabilize the folded protein without competing with the natural substrate, resulting in a net gain of function ...
Barroso M   +11 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy